<DOC>
	<DOCNO>NCT00799006</DOCNO>
	<brief_summary>PF-04620110 novel compound propose treatment Type 2 diabetes mellitus . The purpose study characterize safety , tolerability , pharmacokinetics pharmacodynamics follow single oral dose .</brief_summary>
	<brief_title>A Single Dose Study Of PF-04620110 In Overweight And Obese , Otherwise Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year Body Mass Index ( BMI ) approximately 27 35 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Single Ascending Dose Study Overweight subject</keyword>
</DOC>